Author

R. Alieva

h-index 1 View on Semantic Scholar

We have 3 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Metabolomic phenotype of heart failure in cardio-oncology patients

Heart failure (HF) in cardio-oncology patients during anticancer therapy is usually regarded as an accelerated form of classical HF, which restricts early diagnosis and timely pathogenetically based treatment. Myocardial decompensation in these patients appears to involve distinct molecular mechanisms detectable...

R. Alieva, K. Fozilov, M. Yakhyoeva et al. · European Heart Journal, Supp... · 0 citations

Aug 2026

Endothelin-1 as a diagnostic and prognostic biomarker of subclinical anthracycline-induced vascular toxicity in lymphoproliferative diseases patients with low and intermediate cardiotoxic risk

Endothelin-1 is a promising early diagnostic and prognostic biomarker of subclinical anthracycline-induced vascular toxicity in lymphoma patients with low and intermediate CVT-risk receiving anthracycline-based chemotherapy and may facilitate early risk reclassification and optimization of cardio-oncology surveillance...

R. Alieva, K. Fozilov, M. Yakhyoeva et al. · European Heart Journal, Supp... · 0 citations

Open access Aug 2026

Early lipid profile deterioration during chemotherapy as a marker of subclinical vascular toxicity and therapy rationale

In patients with low and moderate baseline CV risk, a statistically significant deterioration in lipid profile was observed during chemotherapy, which is consistent with the development of subclinical endothelial dysfunction and early vascular toxicity, despite the absence of overt clinical manifestations of vasculotox...

R. Alieva, K. Fozilov, M. Yakhyoeva et al. · European Heart Journal, Supp... · 0 citations